Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PULSE BIOSCIENCES, INC.
Report date December 11, 2024 · Filed December 20, 2024
Section 16 reporting ended · disclosed 2024-12-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,172 |
Reported balance
After 2024-12-11 transaction · row 1
1 source rowRow 1 · 2024-12-11 · Sale · Disposed 50,000 · Balance 63,172 F1: As part of this transaction, Mr. Barrett has agreed to voluntarily disgorge the short swing profits realized by Mr. Barrett as a result of the sale of shares disclosed hereby and his prior purchase of 1,086 units in the Company's right's offering earlier this year. Prior to filing this Form 4, Mr. Barrett contacted the Issuer to make arrangements for payment of such disgorgement. |
Filing footnotes · ownership attribution and instrument terms
F1: As part of this transaction, Mr. Barrett has agreed to voluntarily disgorge the short swing profits realized by Mr. Barrett as a result of the sale of shares disclosed hereby and his prior purchase of 1,086 units in the Company's right's offering earlier this year. Prior to filing this Form 4, Mr. Barrett contacted the Issuer to make arrangements for payment of such disgorgement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2024 Filed Dec 20, 2024 17:00 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 50,000 | $17.42 | $871,000.00 |
DisclosureSEC source: 0001437749-24-038145 · rdgdoc.xml · nonDerivative · entry 1 Barrett Burke Thomas · CIK 0002023875 · Former President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,172 F1 · kind: As part of this transaction, Mr. Barrett has agreed to voluntarily disgorge the short swing profits realized by Mr. Barrett as a result of the sale of shares disclosed hereby and his prior purchase of 1,086 units in the Company's right's offering earlier this year. Prior to filing this Form 4, Mr. Barrett contacted the Issuer to make arrangements for payment of such disgorgement. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 21:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 543 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001437749-24-023232 · rdgdoc.xml · derivative · entry 4 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 543 shares Expires 2029-07-03 Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 21:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 543 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001437749-24-023232 · rdgdoc.xml · derivative · entry 3 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 543 shares Expires 2029-07-03 Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 21:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 543 | $11.00 | $5,973.00 |
DisclosureSEC source: 0001437749-24-023232 · rdgdoc.xml · nonDerivative · entry 2 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,172 Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 21:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 543 | $11.00 | $5,973.00 |
DisclosureSEC source: 0001437749-24-023232 · rdgdoc.xml · nonDerivative · entry 1 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,629 Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 21:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 543 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022339 · rdgdoc.xml · derivative · entry 3 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543 Underlying: Common Stock · 543 shares Expires 2029-07-03 F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 21:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 543 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022339 · rdgdoc.xml · derivative · entry 2 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543 Underlying: Common Stock · 543 shares Expires 2029-07-03 F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 21:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 1,086 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022339 · rdgdoc.xml · nonDerivative · entry 1 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,086 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| May 20, 2024 Filed May 22, 2024 14:07 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,000 | $8.56 | $85,600.00 |
DisclosureSEC source: 0001437749-24-017966 · rdgdoc.xml · nonDerivative · entry 1 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: Volume-weighted average price. Read SEC document |
| May 12, 2024 Filed Jun 24, 2024 19:31 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001437749-24-021123 · rdgdoc.xml · derivative · entry 2 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2034-05-12 F2 · derivative.exercise_date: The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone. Read SEC document |
| May 12, 2024 Filed Jun 24, 2024 19:31 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001437749-24-021123 · rdgdoc.xml · derivative · entry 1 Barrett Burke Thomas · CIK 0002023875 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2034-05-12 F1 · derivative.exercise_date: The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.